- Home
- UAC vs KLRS Comparison
UAC vs KLRS Comparison
Compare UAC & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$3.42
Company Overview
Basic Information| Metric | UAC | KLRS |
|---|---|---|
| Founded | 2025 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.6M | 113.0M |
| IPO Year | 2026 | N/A |
Fundamental Metrics
Financial Performance| Metric | UAC | KLRS |
|---|---|---|
| Price | $9.94 | $3.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 2.0K | ★ 630.7K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.51 | $2.14 |
| 52 Week High | $9.99 | $11.88 |
Technical Indicators
Market Signals| Indicator | UAC | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 32.70 |
| Support Level | $9.51 | N/A |
| Resistance Level | $9.97 | $5.48 |
| Average True Range (ATR) | 0.02 | 0.48 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 44.44 | 13.04 |
Price Performance
Historical Comparison UAC
KLRS
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.